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Altered striatal dopaminergic neurotransmission is thought to be fundamental to schizophrenia.
Increased presynaptic dopaminergic activity ([18F]–DOPA PET) may predate the onset of psychotic
symptoms and correlates to clinical symptoms in subjects at Ultra High Risk (UHR) for developing
psychosis. Postsynaptic dopaminergic neurotransmission has not been investigated yet in UHR
patients. We hypothesized that synaptic dopamine concentration would be increased in UHR
patients, and that synaptic dopamine concentration would be related to symptom severity. 14 UHR
patients and 15 age and IQ matched controls completed an [123I]–IBZM SPECT scan at baseline and
again after dopamine depletion with alpha-methyl-para-tyrosine (AMPT). We measured changes in
radiotracer binding potential, compared these between UHR patients and controls, and correlated
these to symptom severity. The UHR group as a whole did not differ signiﬁcantly from controls.
AMPT signiﬁcantly reduced symptom severity in the UHR group (p=0.014). Higher synaptic
dopamine concentration predicted larger reduction of positive symptoms following depletion in
the UHR group (p=0.01). In UHR patients, positive symptoms responded to dopamine depletion,
comparable to observations in schizophrenia, suggesting a similar mechanism. Higher synaptic
dopamine concentration was associated with more severe positive symptoms and a greater
reduction of these symptoms following depletion.
& 2012 Elsevier B.V. and ECNP. All rights reserved.Elsevier B.V. and ECNP. All rights
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Schizophrenia typically emerges in late adolescence, and is
characterized by disturbances in perception, thought, volitionreserved.
Depletion SPECT in UHR subjects 127and cognition. It is usually preceded by a prodromal period,
with mild positive psychotic and negative symptoms, non-
speciﬁc symptoms and a decline in psychosocial functioning.
Researchers in Australia, USA and Germany developed instru-
ments for assessment of symptoms and signs that predicted
transition to psychosis prospectively (Klosterkotter et al.,
2001; Miller et al., 2003; Yung et al., 2003). Recently, these
ﬁndings were replicated with transition rates varying from 10%
to 40% after a two-year follow-up (Cannon et al., 2008;
Ruhrmann et al., 2010; Yung et al., 2008). Patients in these
studies were described to have an At Risk Mental State (ARMS)
or have an Ultra High Risk (UHR) to develop psychosis.
Currently there is no proven therapy or strategy to prevent
transition to psychosis (de Koning et al., 2009).
Dopamine receptors have been a focus in schizophrenia
research as they are the target of anti-psychotic drugs.
Imaging studies have shown direct evidence of disruption of
dopaminergic neurotransmission in the striatum of patients
with schizophrenia and this is thought to be fundamental to
development of psychotic symptoms. More speciﬁcally, the
majority of [18F]–DOPA positron emission tomography (PET)
studies showed increased striatal DOPA uptake (Howes et al.,
2007) and dopamine depletion studies showed increased
occupancy of striatal dopamine D2/3 receptors by endogenous
dopamine in patients with schizophrenia compared to controls
(Abi-Dargham et al., 2000, 2009; Kegeles et al., 2010).
An increased presynaptic striatal [18F]–DOPA uptake has
recently been demonstrated in UHR patients (Howes et al.,
2009), UHR patients that later develop psychosis (Howes
et al., 2011a), and has been related to abnormal frontal
brain function (Fusar-Poli et al., 2010) and hippocampal
glutamate levels (Stone et al., 2010; Bloemen et al., 2011).
Also presynaptic striatal [18F]–DOPA has been reported to be
increased after transition to psychosis (Howes et al.,
2011b). However to our knowledge synaptic dopamine
concentration using dopamine depletion has not yet been
investigated in UHR patients.
[123I]–IBZM Single Photon Emission Computed Tomography
(SPECT) imaging measures the in-vivo binding of [123I]–IBZM
to striatal dopamine D2/3 receptors not occupied by endo-
genous dopamine. Synaptic dopamine concentration, or
occupancy of D2/3 receptors by endogenous dopamine, can
be estimated by employing a well-validated challenge
paradigm (Bloemen et al., 2008), which combines a baseline
scan with a second scan following dopamine depletion with
alpha-methyl-para-tyrosine (AMPT). AMPT is a competitive
inhibitor of tyrosine hydroxylase, the rate-limiting enzyme
of catecholamine synthesis. The percentage change in
binding potential between the baseline and depletion is a
proxy of baseline synaptic dopamine concentration.
We hypothesized that synaptic dopamine concentration is
increased in UHR patients, as has been demonstrated in
schizophrenia. We furthermore hypothesized that dopamine
concentration is positively related to symptom severity.2. Methods
2.1. Subjects
Help seeking UHR patients were recruited through our clinical early
psychosis program (Academic Medical Centre, Amsterdam).Inclusion criteria were age between 18 and 35 years and fulﬁllment
of UHR criteria (see below). Healthy control subjects were
recruited through local advertisement.
Exclusion for all participants criteria were: (1) present treatment
with antipsychotic or stimulant medication or previous treatment
for longer than one week, (2) present use (checked by urine drug
screen) or lifetime history of substance dependence or abuse,
(3) neurological disorders, (4) pregnancy (checked by urine test),
(5) participation in research with radioactive load in past year prior
to study. Additional exclusion criteria for healthy controls were:
present or past DSM-IV diagnosis or family history of psychotic
illness. The study was approved by local and national medical ethics
committees and all participants of the study gave written informed
consent after the full procedure had been explained to them.
2.2. Clinical measures
All subjects were assessed by a psychiatrist and a research psychol-
ogist. UHR diagnosis was assessed with the ‘‘Comprehensive Assess-
ment of At Risk Mental State’’ (CAARMS) (Yung et al., 2004). At the
time of imaging all patients were assessed using the following
instruments: the Positive and Negative Syndrome Scale (PANSS) for
Schizophrenia to assess symptom severity (Kay et al., 1987),
Structured Clinical Interview for Diagnosis (SCID), sections B and C
(Spitzer et al., 1992) to asses other DSM-IV diagnoses, the Compre-
hensive International Diagnostic Interview (CIDI), sections J and L to
assess substance abuse (World Health Organization, 1993), and
7 subtests of the Wechsler Adult Intelligence Scale-Revised (WAIS-
R) to assess full scale intelligence quotient (FSIQ) (Wechsler, 1987).
2.3. Depletion protocol
Dopamine depletion was induced by oral administration of AMPT
over 24 h. The exact AMPT dose was calculated on a per weight
basis (40 mg/kg body weight, with a maximum of 4 g). This dose was
selected as it induces sufﬁcient depletion while causing minimal
adverse effects (Bloemen et al., 2008; Boot et al., 2008; Hasler
et al., 2008). Three doses were given one day prior to imaging; at
10 a.m., 4 p.m. and 10 p.m. The last AMPT dose was given at 10
a.m., one hour prior to the acquisition of the second SPECT scan. To
prevent the formation of AMPT crystals in the urine, subjects were
instructed to drink plenty of ﬂuids.
2.4. Spect protocol
Participants were not allowed to consume coffee, alcohol or
nicotine on scan days (Kaasinen et al., 2004). All subjects took
potassium iodide orally to block thyroid uptake of free radioactive
iodide. Subjects underwent two SPECT scans with the selective
dopamine D2/3 receptor tracer iodine-123 labeled (S)-(-)-3-iodo-
2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide
([123I]–IBZM), using the sustained equilibrium/constant infusion
technique (Laruelle et al., 1995). A total [123I]–IBZM dose (speciﬁc
activity 4200 MBq/nmol and radiochemical purity 495% produced
according to GMP criteria at GE Healthcare, Eindhoven, The
Netherlands) of approximately 80 MBq was given as a bolus,
followed by continuous infusion of approximately 20 MBq per hour
for the duration of the experiment. The bolus to hourly infusion
ratio was approximately 4.0 (Booij et al., 1997). SPECT data were
acquired for approximately 60 min, from 120 to 180 min after the
initiation of [123I]–IBZM administration. SPECT studies were per-
formed using a brain-dedicated scanner (Neurofocus 810, upgrade
of Strichmann Medical Equipment). Axial slices were acquired in
5 mm steps as earlier described (Boot et al., 1997a, 2008). The ﬁrst
scan was obtained in the absence of pharmacological interven-
tion (baseline scan). The second scan was performed identically
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participated in an earlier magnetic resonance spectroscopy study
(Bloemen et al., 2011).2.5. Peripheral measures
Blood samples were taken at 9 a.m. (baseline) before administering
[123I]–IBZM on the baseline day and at 9 a.m. (pre-SPECT) and 12
a.m. (post-SPECT) on the depletion day for determination of plasma
levels of prolactin and homovanillic acid. Urine samples were
collected at the same times for determination of dopamine.
Prolactin was measured as earlier described (Boot et al., 2008).
The total assay variation ranged from 5.8% to 7.6%. Homovanillic
acid levels were measured as earlier described (Boot et al., 2008).
Intra- and inter-assay variations, calculated on low, mid, and high
levels, ranged from 1.2% to 7.8% (intra-assay) and 4.8–10.4% (inter-
assay) respectively. Concentrations of dopamine in urine were
determined as earlier described (Abeling et al., 1984; Stroomer
et al., 1990). Dopamine variation ranged from 2.4% to 4.1% (intra-
assay) and 2.7–6.7% (inter-assay). Plasma AMPT levels were mea-
sured using gas chromatography/mass spectrometry. Inter- and
intra-assay coefﬁcient of variation was less than 5%.2.6. Image reconstruction and analysis
SPECT data were reconstructed and analyzed by a single blinded
investigator. Images were corrected for attenuation and recon-
structed in three-dimensional mode, as earlier described (Booij
et al., 1997b). For quantiﬁcation, region-of-interest (ROI) analyses
were performed. Fixed ROI templates were used for left and right
striatum and occipital cortex and placed on four consecutive axial
slices containing the highest striatal binding. Individual variation
required movement of the ﬁxed ROIs, without changing size and
shape, for optimal ﬁtting.
Mean activation across all slices was calculated for the striatum
(representing speciﬁc binding) and for the occipital reference region
(representing non-speciﬁc/non-displaceable binding). The binding
potential was calculated as the ratio of speciﬁc to non-speciﬁc activity
(total activity in striatum minus activity in occipital cortex, divided by
activity in occipital cortex) (BPND) (Innis et al., 2007). To assess the
synaptic dopamine concentration (DBPND), the difference betweenTable 1 Demographic variables.
Variable UHR group
N 14f
Gender (M/F)a 12/4
Age in years (average7S.D.) 21.99
Weight in kg (average7S.D.) 77.32
FSIQ (average7S.D.)b 104.67
PANSS positive totalc baseline 12.36
PANSS positive totald depletion (N=14) 10.43
PANSS total baseline 50.29
PANSS total depletion (N=14) 47.43
aM=male, F=female.
bFull-scale intelligence quotient measured by seven subtests of th
cTotal of the positive symptom sub-scores of the PANSS.
dTotal of all sub-scores of the PANSS.
eStandard deviation.
fFor the demographics 14 subjects were used, because for analysi
nSigniﬁcantly different between UHR and controls.BPND after depletion and BPND at baseline was expressed as percentage
change in BPND compared to baseline BPND (Abi-Dargham et al., 2000).2.7. Statistical analyses
Demographic variables were analyzed using independent t-tests or
chi-square test as appropriate. All variables were tested for
normality, and parametric or non-parametric tests were used as
appropriate. A probability value of 0.05 (two-tailed) was selected
for all tests. All statistical analyses were performed with SPSS,
release 18.0.0 for Windows (SPSS Inc., Chicago, Illinois, USA, 2009).
Peripheral measures were compared using repeated-measures
analysis of variance (ANOVA). Between-group comparisons of BPND
were done using repeated-measures ANOVA. The group differences
were further explored ‘‘post-hoc’’ using paired-sample t-tests.
AMPT effects on positive PANSS scores were tested with repeated-
measures ANOVA. The relation between percentage change in BPND
and change in positive symptoms (total score on positive subscales
of the PANSS) following AMPT was tested using a linear regression
analysis. Relationships between clinical measures and dopamine
concentration were analyzed using Pearson correlation coefﬁcient.3. Results
3.1. Subjects and demographics
We recruited 16 UHR patients and 15 controls. Two UHR
patients only completed baseline scanning and did not
return for the depletion scan due to anxiety during baseline
imaging and for unknown reason, respectively. Demographic
characteristics and PANSS scores are listed in Table 1.3.2. Adverse and clinical effects
None of the subjects had to be withdrawn due to side
effects. One UHR subject experienced an anxiety attack
after AMPT depletion, but completed the depletion SPECT
on another day. Some UHR patients reported feeling better
after taking AMPT. AMPT signiﬁcantly decreased positiveS.D.e Controls S.D.e p-Value
15
13/2 0.65
3.94 22.17 3.54 0.75
17.55 77.73 15.05 0.97
12.51 111.47 18.62 0.31
2.90 7.07 0.28 o0.001n
3.18 7.00 0.00 0.001n
13.57 30.79 2.16 o0.002n
14.66 31.14 2.00 0.003n
e abbreviated Wechsler adult intelligence scale-III.
s using depletion scan data only 14 subjects had data available.
Figure 1 Correlation PANSS positive symptom scores and the
percentage change in binding potential (BPND) in the UHR and
the control group.
Depletion SPECT in UHR subjects 129PANSS scores in the UHR group (mean=1.92, S.D.=2.56,
p=0.014, eta2=0.38).
We found a signiﬁcant main effect of AMPT on positive
PANSS scores in the UHR group (F(1,12)=10.38, p=0.007,
partial eta2=0.46). High striatal synaptic dopamine concen-
tration predicted good response of positive symptoms to
AMPT in the UHR group (r2=0.56, p=0.01).
3.3. D2/3 receptor binding
There was no statistically signiﬁcant AMPT x group interaction
(F(1,27)=1.25, p=0.27) for BPND. The main effect of AMPT on
BPND was signiﬁcant (F(1,27)=5.09, p=0.03, partial eta
2=0.16),
but there was no signiﬁcant effect of group on BPND
(F(1,27)=0.001, p=0.976). Percentage change in BPND was
5.20% (S.D.=21) for UHR patients and 10.94% (S.D.=13) for
controls, but did not differ signiﬁcantly between the two groups
(t(20.7)=0.87, p=0.394). There was no signiﬁcant difference
between groups in BPND at baseline (t(29)=0.45; p=0.66) or
after depletion (t(27)=0.64; p=0.53) (Table 2). Levene’s Test
for Equality of Variances indicated unequal variances in the
percentage change in BPND (F=4.40, p=0.046).
Percentage change in BPND was signiﬁcantly correlated to
baseline total CAARMS positive subscale scores (r=0.78,
p=0.001), baseline PANSS total (r=0.57, p=0.032), baseline
PANSS positive subscales (r=0.75, p=0.002) (Figure 1) in the
UHR group, whereas there was no signiﬁcant correlation
between percentage change in BPND and baseline PANSS positive
subscales (r=0.09, p=0.77) and baseline PANSS total scores
(r=0.06, p=0.84) in the control group.
3.4. Peripheral measures
There was a statistically signiﬁcant decrease of dopamine
and homovanillic acid and an increase of prolactin after AMPT,
but no between-group differences (Table 3), dopamine:
AMPT group interaction (F(1,24)=1.36, p=0.25), main effect
of AMPTon dopamine (F(1,24)=298.55, p=o0.001, eta2=0.93),
main effect of group on dopamine (F(1, 24)=4.08, p=0.055).
Homovanillic acid: AMPT group interaction (F(1,25)=1.90,
p=0.18), main effect of AMPT on homovanillic acid (F(1,25)=
80.80, p=o0.001, eta2=0.76), main effect of group onTable 2 [123I]–IBZM binding potential (BPND) at baseline and fo
Group
Baseline condition Control group
UHR group
Depletion condition Control group
UHR group
Percentage change after depletion Control group
UHR group
aMean binding potential.
bStandard deviation.
cp-Value for the comparison between UHR patients and controls.homovanillic acid (F(1, 25)=0.52, p=0.48). Prolactin: AMPT
group interaction (F(1,26)=0.36, p=0.55), main effect of AMPT
on prolactin (F(1,26)=50.50, p=o0.001, eta2=0.67), main
effect of group on prolactin (F(1, 26)=0.94, p=0.34).4. Discussion
This is the ﬁrst study to use the dopamine depletion paradigm
to measure baseline striatal dopamine neurotransmission in
drug-na¨ıve UHR patients. Our results demonstrate that the
AMPT depletion paradigm achieved sufﬁcient depletion; AMPT
induced (1) a statistically signiﬁcant increase in BPND in the
combined sample and in controls, (2) signiﬁcant symptom
reduction on the PANSS in UHR patients, (3) a signiﬁcantllowing AMPT administration.
n Meana S.D.b p-Value
15 0.82 0.12
16 0.84 0.15 0.66c
15 0.90 0.11
14 0.87 0.13 0.53c
15 10.94 12.60
14 5.20 21.47 0.39c
Table 3 Pharmacological measures taken from blood and urine samples of participants.
Variable Baselinee S.D.h Pre-SPECTf Mean value7S.D. S.D.h
S.D.h Post-SPECTg
AMPTa – – 8.34 2.01 15.37 3.45
Dopamineb 145.58 29.60 79.3 23.68 76.77 27.13
Prolactinc 14.31 5.79 24.93 6.90 38.21 17.48
Homovanillic acidd 68.62 30.39 33.54 15.02 21.25 9.99
aAlpha-methyl-para-tyrosine, measured in mg/L in plasma.
bDopamine measured in nmol/mmol kreatinine in urine.
cProlactin measured in mg/L in plasma.
dHomovanillic acid nmol/L in plasma.
eBaseline=day 1 at 9 a.m.
fPre-SPECT=day 2 at 9 a.m.
gPost-SPECT=day 2 at 12 a.m.
hStandard deviation.
O.J.N. Bloemen et al.130correlation between PANSS scores and synaptic dopamine
concentration in UHR patients, (4) high synaptic dopamine
concentration predicted good response of positive symptoms
to AMPT in UHR patients, and (5) a signiﬁcant increase in
prolactin and signiﬁcant decrease in dopamine and homova-
nillic acid. However, our results suggest that UHR patients are
a heterogeneous group and that this may partially explain why
we did not ﬁnd between-group differences in dopaminergic
neurotransmission.
Doses of AMPTused in challenge studies have been variable.
Some groups used relatively high AMPT doses (Abi-Dargham
et al., 2009; Martinez et al., 2009; Verhoeff et al., 2001),
which may lead to more pronounced side-effects and may
cause subjects to drop out of the study (Bloemen et al., 2011;
de Haan et al., 2005). We have shown previously that lower
doses (40 mg/kg) of AMPT achieve a satisfactory central and
peripheral dopaminergic depletion with few side effects (Boot
et al., 2008). In the present study depletion of dopamine with
AMPT signiﬁcantly decreased dopamine in urine and homo-
vanillic acid in plasma, and signiﬁcantly increased plasma
prolactin. Homovanillic acid was decreased by approximately
70% in both UHR and controls, in line with previous AMPT
depletion literature (Laruelle et al., 1997; Martinez et al.,
2009; Verhoeff et al., 2001). AMPT caused a statistically
signiﬁcant increase in BPND of 10% in controls, which is
comparable to ﬁndings of previous depletion studies (Abi-
Dargham et al., 2000, 2009; Martinez et al., 2009; Riccardi
et al., 2008).
Variance in BPND was signiﬁcantly larger in the UHR group
(as shown by Levene’s Test for Equality of Variance), which
underlines the heterogeneity of the group. This increased
variance is also observed in schizophrenia patients
(Abi-Dargham et al., 2000).
There was no signiﬁcant difference in percentage change in
BPND between UHR patients and healthy controls. A possible
explanation for this is the heterogeneity of the UHR group, as
only 10–40% develop subsequent psychosis. The heterogeneity
of the UHR group is inherent to its concept but decreases our
power to detect differences in BPND. Another speculative
explanation is that the postsynaptic dopaminergic abnormal-
ities seen in schizophrenia (Abi-Dargham et al., 2000, 2009)
may be a later phenomenon caused by the psychosis, followingpresynaptic abnormalities that have been reported in UHR
patients (Howes et al., 2009).
The dopaminergic abnormalities we observed were signiﬁ-
cantly correlated to the amount of positive symptoms they
experience on the CAARMS, and to positive PANSS and to total
PANSS, but not to total CAARMS. Howes and colleagues reported
a correlation between presynaptic striatal dopamine levels and
total CAARMS, but not to positive subscale totals (Howes et al.,
2009). Abi Dargham and colleagues reported no relation
between PANSS scores and striatal dopamine in schizophrenia
(Abi-Dargham et al., 2000). This suggests that presynaptic
dopamine may be more related to overall functioning whereas
postsynaptic dopaminergic neurotransmission may be more
related to positive symptoms. The reason that in schizophrenia
this relationship is lost is unclear, but may be due to longer
duration of symptoms, having had frank psychotic symp-
toms, or to possible ceiling effect of high dopamine and
symptomatology.
It is also interesting that UHR patients with milder symp-
toms appear to have a low percentage change in BPND.
Martinez et al. (2009) recently showed low striatal receptor
occupancy in abstinent cocaine users. Although the patients in
our sample had no history of drug abuse, a similar effect of
AMPTwas seen in the striatum. This ﬁnding suggests that low
striatal receptor occupancy may not be speciﬁc for addiction.
In this context it is of interest that all dopaminergic depletion
imaging studies showed clear variations in striatal receptor
occupancy, also in controls. Future studies should focus on
etiological factors and clinical correlates of this variation.
Dopamine depletion with AMPT signiﬁcantly decreased
positive symptoms in UHR patients as measured by the total
score on the subscales for positive symptoms on the PANSS.
This novel ﬁnding adds to evidence that the positive symptoms
that UHR patients experience are related to dopamine. This
was strengthened by the fact that some of the UHR patients
asked if they could continue AMPT medication (see also
‘‘patient perspectives’’). Furthermore high synaptic dopamine
concentration predicted good response of positive symptoms
to dopamine depletion. This has also been reported in
schizophrenia, and also predicted response to antipsychotic
treatment (Abi-Dargham et al., 2000). This is interesting, in
particular regarding the ongoing discussion about treatment of
Depletion SPECT in UHR subjects 131UHR symptoms (de Koning et al., 2009; McGorry et al., 2009),
as our results suggest there might be a subgroup of UHR
patients with high synaptic dopamine concentration who could
beneﬁt from antipsychotics to treat their current positive
symptoms. Our current data do not allow any conclusions with
regard to transition to psychosis and at this time we are
unable to determine which patients might possibly proﬁt from
medication, although our results suggest some may.
It is unlikely that the greater increase in BPND in UHR
patients with higher positive symptoms is caused by up-
regulation of D2/3 receptors after acute dopamine depletion
with AMPT as previous studies have shown that the duration
of treatment is too short to induce detectable up-regulation
(Laruelle et al., 1997). We can therefore assume that
comparing baseline and depletion BPND is an indirect
measure of the proportion of D2/3 receptors occupied by
dopamine in the baseline state. So what would explain
higher synaptic dopamine concentration? Increased afﬁnity
of the receptors for dopamine could explain this, although
this is not supported by a recent [11C]–(+)–PHNO PET study
(Graff-Guerrero et al., 2009). Graff and colleagues reported
no evidence for elevated D2 receptor afﬁnity in schizophre-
nia patients, although depletion studies are needed to
conﬁrm this was not masked by endogenous dopamine.
Alternatively increased synaptic dopamine concentration
could be caused by increased activity of presynaptic dopa-
minergic neurons levels, which is supported by recent
ﬁndings in UHR patients (Howes et al., 2009).
Furthermore the strong link between positive symptoms and
dopamine in our study suggests that increased synaptic dopa-
mine concentration may not be a risk factor for psychosis but is
co-occurring with increased psychotic symptomatology. Thus, it
may be more indicative of state than of trait of the UHR
patients and these ﬁndings are in line with a dimensional
approach of psychiatric disorders.
This study has several strengths. As the ﬁrst depletion study
in UHR patients studying dopaminergic neurotransmission it
provides unique data about synaptic dopamine concentration
in the striatum, and its relation to symptoms. Furthermore all
subjects were drug-na¨ıve and comparable in age, weight, FSIQ
and sex. We achieved signiﬁcant depletion with a relatively
low AMPT dose and subjects had very little side effects.
Limitations of this study are the small sample size, the
inclusion of mainly male patients, and the failure of two
subjects to complete the depletion scan. Furthermore,
although we achieved depletion as explained above, the
modest dose of AMPT and hence possibly a less complete
depletion may have inﬂuenced our results. We did not
measure activity of dopamine transporters which could have
inﬂuenced synaptic dopamine concentration as well.
In conclusion, the results of this ﬁrst depletion study in UHR
patients suggest that UHR patients with high scores on positive
symptom scales may already have abnormalities in dopami-
nergic neurotransmission. Dopamine depletion leads to sig-
niﬁcant positive symptom reduction in UHR patients, and
synaptic dopamine concentration predicted good response of
positive symptoms to AMPT in UHR patients. Furthermore the
results show that positive symptoms respond to dopamine
depletion in the UHR group as they do in schizophrenia. Our
sample was not assessed longitudinally and therefore transi-
tion into psychosis is not known yet. However, follow-up
studies are now ongoing and will provide information ontransition to psychosis in the UHR group. These data may
elucidate the relation between transition to psychosis and
striatal synaptic dopamine concentration and may eventually
answer the relevant question whether dopamine depletion
studies can predict the transition to psychosis.
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